Natural killer cells of Parkinson's disease patients are set up for activation: A possible role for innate immunity in the pathogenesis of this disease

Parkinsonism and Related Disorders

Volumn 14, Issue 1, 2008, Pages 46-51

  Mihara, Tomoko ^a   Nakashima, Manabu ^a   Kuroiwa, Ataru ^a   Akitake, Yoshiharu ^a   Ono, Kazuhiko ^a   Hosokawa, Masato ^a   Yamada, Tatsuo ^a   Takahashi, Mitsuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Innate immunity; Natural killer (NK); NKG2A; NKG2D; Parkinson's disease

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2A;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INNATE IMMUNITY; LYMPHOCYTE; MALE; NATURAL KILLER CELL; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

AGED; AGED, 80 AND OVER; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, IMMUNOLOGIC; TH1 CELLS; TH2 CELLS;

EID: 38349171225     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.05.013     Document Type: Article

References (45)

1. Polymeropoulos M., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 5321 (1997) 2045-2047
2. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 2 (1998) 106-108
3. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 2 (2004) 164-173
4. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 6676 (1998) 605-608
5. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 6701 (1998) 451-452
6. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 5674 (2004) 1158-1160
7. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 5604 (2003) 256-259
8. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 4 (2004) 595-600
9. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 4 (2004) 601-607
10. Elbaz A., Grigoletto F., Baldereschi M., Breteler M.M., Manubens-Bertran J.M., Lopez-Pousa S., et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EURO PARKINSON Study Group. Neurology 52 9 (1999) 1876-1882
11. Rowe D.B., Le W., Smith R.G., and Appel S.H. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 53 5 (1998) 551-558
12. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180 2 (1994) 147-150
13. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165 1-2 (1994) 208-210
14. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 8 (1988) 1285-1291
15. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 4 (1999) 598-605
16. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 8 (2003) 1059-1064
17. Gorell J.M., Johnson C.C., and Rybicki B.A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970-1990. Neurology 44 10 (1994) 1865-1868
18. Vanacore N., Spila-Alegiani S., Raschetti R., and Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52 2 (1999) 395-398
19. D'Amelio M., Ragonese P., Morgante L., Epifanio A., Callari G., Salemi G., et al. Tumor diagnosis preceding Parkinson's disease: a case-control study. Mov Disord 19 7 (2004) 807-811
20. West A.B., Dawson V.L., and Dawson T.M. To die or grow: Parkinson's disease and cancer. Trends Neurosci 28 7 (2005) 348-352
21. Elbaz A., Peterson B.J., Bower J.H., Yang P., Maraganore D.M., McDonnell S.K., et al. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 20 6 (2005) 719-725
22. Yamada T., McGeer P.L., and McGeer E.G. Levy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 84 1 (1992) 100-104
23. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72 2 (1996) 355-363
24. Mattammal M.B., Strong R., Lakshmi V.M., Chung H.D., and Stephenson A.H. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 64 4 (1995) 1645-1654
25. Bokor M., Farago A., Garam T., Malatinszky G., and Schnabel R. Antibody-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease. J Neurol Sci 115 1 (1993) 47-50
26. Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 55 3 (2002) 221-228
27. Moretta L., Biassoni R., Bottino C., Mingari M.C., and Moretta A. Natural killer cells: a mystery no more. Scand J Immunol 55 3 (2002) 229-232
28. McQueen K.L., and Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 14 5 (2002) 615-621
29. Diefenbach A., and Raulet D.H. Innate immune recognition by stimulatory immunoreceptors. Curr Opin Immunol 15 1 (2003) 37-44
30. Lazetic S., Chang C., Houchins J.P., Lanier L.L., and Phillips J.H. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 157 11 (1996) 4741-4745
31. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 6669 (1998) 795-799
32. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 5428 (1999) 727-729
33. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 2 (2001) 123-133
34. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18 5 (2003) 467-486
35. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 5 (1967) 427-442
36. Petrovsky N., and Harrison L.C. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type1/T helper cell type 2 balance?. J Immunol 158 11 (1997) 5163-5168
37. Zhang C., Zhang J., Sun R., Feng J., Wei H., and Tian Z. Opposing effect of IFNγ and IFNα on expression of NKG2 receptors: negative regulation of IFNγ on NK cells. Int Immunopharmacol 5 6 (2005) 1057-1067
38. Su H.C., Nguyen K.B., Salazar-Mather T.P., Ruzek M.C., Dalod M.Y., and Biron C.A. NK cell functions restrain T cell responses during viral infections. Eur J Immunol 31 10 (2001) 3048-3055
39. Salazar-Mather T.P., Ishikawa R., and Biron C.A. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J Immunol 157 7 (1996) 3054-3064
40. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. Evidence for resistance to MPTP in C57BL/6×BALB/c F1 hybrids as compared with their progenitor strains. Neuroreport 11 5 (2001) 1093-1096
41. Haobam R., Sindhu K.M., Chandra G., and Mohanakumar K.P. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res 163 2 (2005) 159-167
42. Zhang Y., Lamm W.J., Albert R.K., Chi E.Y., Henderson Jr. W.R., and Lewis D.B. Influence of the route of allergen administration and genetic background on the murine allergic pulmonary response. Am J Respir Crit Care Med 155 2 (1997) 661-669
43. Levitt R.C., Mitzner W., and Kleeberger S.R. A genetic approach to the study of lung physiology: understanding biological variability in airway responsiveness. Am J Physiol 258 4 Pt 1 (1990) L157-L164
44. Wilder J.A., Collie D.D., Wilson B.S., Bice D.E., Lyons C.R., and Lipscomb M.F. Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma. Am J Respi Cell Mol Biol 20 6 (1999) 1326-1334
45. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., and Yamada T. Alterations of T-lymphocyte populations in Parkinson's disease. Parkinsonism Relat Disord 11 8 (2005) 493-498